These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 1501121)
1. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. Rinaldi-Carmona M; Congy C; Santucci V; Simiand J; Gautret B; Neliat G; Labeeuw B; Le Fur G; Soubrie P; Breliere JC J Pharmacol Exp Ther; 1992 Aug; 262(2):759-68. PubMed ID: 1501121 [TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067. Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993 [TBL] [Abstract][Full Text] [Related]
3. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro. Germonpré PR; Joos GF; Pauwels RA Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563 [TBL] [Abstract][Full Text] [Related]
4. Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain. Rinaldi-Carmona M; Congy C; Simiand J; Oury-Donat F; Soubrie P; Breliere JC; Le Fur G Mol Pharmacol; 1993 Jan; 43(1):84-9. PubMed ID: 8423772 [TBL] [Abstract][Full Text] [Related]
5. Regulation of 5-hydroxytryptamine2 (5-HT2) receptor expression in cultured rat aortic smooth muscle cells by SR 46349B, a selective 5-HT2 receptor antagonist. Rinaldi-Carmona M; Prabonnaud V; Bouaboula M; Poinot-Chazel C; Casellas P; Le Fur G; Herbert JM J Biol Chem; 1994 Jan; 269(1):396-401. PubMed ID: 8276825 [TBL] [Abstract][Full Text] [Related]
6. Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist. Rinaldi-Carmona M; Bouaboula M; Congy C; Oury-Donat F; Simiand J; Shire D; Casellas P; Soubrié P; Brelière JC; Le Fur G Eur J Pharmacol; 1993 Jun; 246(1):73-80. PubMed ID: 8354344 [TBL] [Abstract][Full Text] [Related]
7. Identification of binding sites for SR 46349B, a 5-hydroxytryptamine2 receptor antagonist, in rodent brain. Rinaldi-Carmona M; Congy C; Pointeau P; Vidal H; Brelière JC; Le Fur G Life Sci; 1994; 54(2):119-27. PubMed ID: 8277817 [TBL] [Abstract][Full Text] [Related]
8. Further evidence that various 5-HT receptor subtypes modulate central respiratory activity: in vitro studies with SR 46349B. Monteau R; Di Pasquale E; Hilaire G Eur J Pharmacol; 1994 Jun; 259(1):71-4. PubMed ID: 7957597 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of a new 5-hydroxytryptamine2 receptor antagonist, DV-7028. Shibano T; Tanaka T; Morishima Y; Yasuoka M; Watanabe K; Fujii F Arch Int Pharmacodyn Ther; 1992; 319():114-28. PubMed ID: 1285670 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist. Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049 [TBL] [Abstract][Full Text] [Related]
11. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Dumuis A; Bouhelal R; Sebben M; Cory R; Bockaert J Mol Pharmacol; 1988 Dec; 34(6):880-7. PubMed ID: 2849052 [TBL] [Abstract][Full Text] [Related]
12. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558 [TBL] [Abstract][Full Text] [Related]
13. Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle. Cohen ML; Schenck KW; Colbert W; Wittenauer L J Pharmacol Exp Ther; 1985 Mar; 232(3):770-4. PubMed ID: 3973826 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery. Hamel E; Robert JP; Young AR; MacKenzie ET J Pharmacol Exp Ther; 1989 Jun; 249(3):879-89. PubMed ID: 2732950 [TBL] [Abstract][Full Text] [Related]
15. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity. Millan MJ; Bervoets K; Colpaert FC J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two different arterial tissues suggests possible 5-hydroxytryptamine2 receptor heterogeneity. Killam AL; Nikam SS; Lambert GM; Martin AR; Nelson DL J Pharmacol Exp Ther; 1990 Mar; 252(3):1083-9. PubMed ID: 2319460 [TBL] [Abstract][Full Text] [Related]
17. Effect of 5-hydroxytryptamine3 receptor agonists on phosphoinositides hydrolysis in the rat fronto-cingulate and entorhinal cortices. Edwards E; Harkins K; Ashby CR; Wang RY J Pharmacol Exp Ther; 1991 Mar; 256(3):1025-32. PubMed ID: 1848625 [TBL] [Abstract][Full Text] [Related]
18. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity. Cushing DJ; Cohen ML J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526 [TBL] [Abstract][Full Text] [Related]